Physician profile
Wassim Abida
NPI 1518101096
$16,166.49
in general payments reported to CMS, 2019-2025
14 companies · $3,795 in 2025
The $3,795 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $1,455 · 2021: $1,595 · 2022: $1,935 · 2023: $6,525 · 2025: $3,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,330 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,700 · Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,330.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,700.00 |
| Food and Beverage | $290.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,700.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $2,660.00 | 2021-2023 | |
| Tolmar, INC. | $2,500.00 | 2025 | |
| Daiichi Sankyo INC. | $1,455.00 | 2020 | |
| Astrazeneca Uk Limited | $1,110.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $1,005.00 | 2025 | |
| Genzyme Corporation | $719.65 | 2019 | |
| Clovis Oncology, INC. | $585.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $290.25 | 2025 | |
| Janssen Biotech, INC. | $124.90 | 2019 | |
| Abbvie INC. | $16.69 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wassim Abida listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.